1
|
Badzio A, Jassem J, Kurowski K, Karnicka-Młodkowska H. 180. The role of surgery in management of limited disease (LD) small cell lung cancer (SCLC), a retrospective comparative study. Rep Pract Oncol Radiother 2003. [DOI: 10.1016/s1507-1367(03)70664-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
2
|
Jassem J, Ramlau R, Karnicka-Młodkowska H, Krawczyk K, Krzakowski M, Zatloukal P, Lemarié E, Hartmann W, Novakova L, O'Brien M, Depierr A. A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients. Ann Oncol 2001; 12:1375-81. [PMID: 11762807 DOI: 10.1023/a:1012539225493] [Citation(s) in RCA: 82] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
PURPOSE A randomized phase II trial of oral vs. intravenous (i.v.) vinorelbine was designed to determine the efficacy and safety of oral vinorelbine with an intrapatient dose escalation in previously untreated patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS Between December 1997 and April 1999, 115 patients with stage IIIB or IV NSCLC were randomized (2 to 1) to receive either oral vinorelbine at a dose of 60 mg/m2/week for the first three administrations and then increased to 80 mg/m2/week in the absence of severe neutropenia, or i.v. vinorelbine at 30 mg/m2/week. RESULTS One hundred and fourteen patients (76 in the oral arm and 38 in the i.v. arm) were treated. Ninety-eight patients (86%) were eligible and assessable. The two treatment arms were well-balanced for demographic and prognostic features. After external panel review, the response rates in evaluable patients were 14%, in the oral arm and 12% in the i.v. arm. The median progression-free survival with oral and i.v. vinorelbine was 3.2 months and 2.1 months, respectively, and the median survival 9.3 and 7.9 months, respectively. The most common hematological toxicity was neutropenia, which was severe (grade 3-4) in 46% of patients and for 7% of administrations in the oral arm, and in 62% of patients and for 25% of administrations in the i.v. arm. Non-hematological toxicities including nausea, vomiting, anorexia, weight loss, diarrhea .and constipation were generally mild to moderate. CONCLUSION The activity of oral and i.v. vinorelbine in advanced NSCLC appears to be comparable. The safety profiles of both formulations look qualitatively similar. Oral vinorelbine can therefore be considered a good alternative to i.v. administration.
Collapse
Affiliation(s)
- J Jassem
- Department of Oncology and Radiotherapy, Medical University of Gdańsk, Poland.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Jereczek-Fossa B, Jassem J, Karnicka-Młodkowska H, Badzio A, Moś-Antkowaik R, Krawczyk K, Kowal E, Pilarska-Machowicz A, Radzikowska E, Malak K. Does chemotherapy-induced leukopenia predict a response in small-cell lung cancer? J Cancer Res Clin Oncol 1998; 124:106-12. [PMID: 9654193 DOI: 10.1007/s004320050141] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
The correlation between chemotherapy-induced toxicity and treatment outcome in cancer patients has not been studied thoroughly. Our aim was to evaluate whether there is any relationship between chemotherapy-induced leukopenia and response to treatment in small-cell lung cancer (SCLC). Data derived from records of 228 patients treated within two prospective multicentre phase II studies were analysed. In the first study (101 patients) chemotherapy included vincristine, epirubicin and cyclophosphamide and, in the second (127 patients), cyclophosphamide, etoposide and epirubicin; both regimens were given every 3 weeks. In the present analysis, the correlation between treatment outcome (response rate and survival) and highest scores of leukopenia within the first two and up to the fourth chemotherapy cycle, respectively, was evaluated. The objective response rate for the entire group was 66%; 53% in patients whose white blood cells remained normal and 85% in those who developed leukopenia within the first two cycles (P = 0.000). In multifactorial analysis, also including other treatment- and patient-related factors, independent correlation with response to chemotherapy was found for leukopenia (P = 0.001), chemotherapy regimen (P = 0.002) and the combined relative dose intensity (P = 0.018), but not for patient sex, age, performance status, pre-study weight loss, extent of disease and initial white blood cell count. Leukopenia within the first two cycles of chemotherapy was not correlated with survival, whereas such correlation for leukopenia occurring up to the fourth cycle was at the borderline level (P = 0.06). These findings suggest a relationship between chemotherapy-induced leukopenia and tumour response in SCLC.
Collapse
Affiliation(s)
- B Jereczek-Fossa
- Department of Oncology and Radiotherapy, Medical University of Gdańsk, Poland.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Jassem J, Karnicka-Młodkowska H, Jassem E, Słupek A, Zych J, Wiatr E, Malak S, Moś-Antkowiak R, Szymaczek-Meyer L, Pilarska-Machowicz A. Combination chemotherapy with cyclophosphamide, epirubicin and etoposide in small cell lung cancer. Lung Cancer 1994; 11:283-91. [PMID: 7812705 DOI: 10.1016/0169-5002(94)90548-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
From March 1987 to February 1991, 136 patients with untreated small cell lung cancer (64 patients with limited disease and 72 with extensive disease), were treated as part of a prospective multi-center study, with a combination of cyclophosphamide 1000 mg/m2 i.v. on day 1, epirubicin 70 mg/m2 i.v. on day 1 and etoposide 100 mg/m2 i.v. on days 1, 3 and 5. Courses were repeated every 3 weeks. One-hundred thirty-four patients were evaluable. There were 42 (31%) complete responses and 66 (49%) partial responses for an overall response rate of 80% (95% confidence interval 71-87%). A complete response was seen in 24 patients (38%) with limited disease and in 18 patients (26%) with extensive disease, while a partial response was observed for 31 (48%) and in 35 (50%) patients, respectively. The median duration of response for all patients was 8.9 months (range, 1-60+ months). The median duration of survival for the entire group was 11.4 months (12.5 months for limited disease and 9.8 months for extensive disease). The 2-year survival rate for the whole group was 13%. The main side-effects were myelosuppression, alopecia, nausea and vomiting. Grade 4 toxicity was seen in 8.5% of patients. In conclusion, the studied regimen was found to be active and well tolerated and may be considered as an alternative to standard chemotherapy combinations in SCLC.
Collapse
Affiliation(s)
- J Jassem
- Department of Oncology and Radiotherapy, Gdansk Medical School, Poland
| | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Jereczek B, Jassem J, Karnicka-Młodkowska H, Badzio A, Slupek A, Lisowska B, Malak S, Sosnowski K, Fabezak J, Pilarska-Machowicz A, Szymaczek-Meyer L. Patterns of failure in small cell lung cancer (SCLC). Lung Cancer 1993. [DOI: 10.1016/0169-5002(93)90642-b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
6
|
Jassem J, Karnicka-Młodkowska H, van Pottelsberghe C, van Glabbeke M, Noseda MA, Ardizzoni A, Gozzelino F, Planting A, van Zandwijk N. Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group. Eur J Cancer 1993; 29A:1720-2. [PMID: 8398301 DOI: 10.1016/0959-8049(93)90112-s] [Citation(s) in RCA: 49] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
26 previously treated patients with progressive recurrent small cell lung cancer (SCLC) were given vinorelbine (Navelbine), 30 mg/m2 weekly. All patients had responded to first-line chemotherapy and were off therapy for at least 3 months. Partial response was observed in 4 out of 25 eligible patients (16%; 95% confidence interval 4-36%), stable disease in 7 patients and progression in 12 patients. The limiting toxicity was a non-cumulative leucopenia (80%, 32% WHO grade 3-4). Reaction at the site of injection was observed in 5 patients, causing treatment discontinuation in 2 cases. Other non-haematological toxicities were moderate. These results suggest acceptable toxicity and some antitumour activity of vinorelbine in pretreated SCLC patients.
Collapse
|
7
|
Jassem J, Karnicka-Młodkowska H, Drozd-Lula M, Strug A, Pilarska-Machowicz A, Michalski A, Kowal E, Moś-Antkowiak R, Zych J. Combination chemotherapy with vincristine, epirubicin and cyclophosphamide in small cell lung carcinoma. Polish Lung Cancer Cooperative Group. Eur J Cancer 1992; 28:473-6. [PMID: 1317199 DOI: 10.1016/s0959-8049(05)80079-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The aim of this prospective study was to assess the activity of a combination of vincristine, epirubicin and cyclosphosphamide (VEC) in previously untreated patients with limited small cell lung carcinoma (SCLC) and to delineate the feasibility of dose escalation for epirubicin in this regimen. The chemotherapy schedule included cyclophosphamide, 1000 mg/m2, vincristine, 1 mg/m2 and escalating doses of epirubicin: 50 mg/m2, 70 mg/m2 and 90 mg/m2; respectively in three consecutive groups of patients. Drug cycles were repeated every 3 weeks. 118 patients from eight institutions were enrolled in this study between February 1986 and March 1989. Objective tumour response was observed in 81 of 116 evaluable patients (70%) including 25 patients (22%) who achieved a complete remission. Responding patients received thoracic radiation after the fourth cycle of chemotherapy. The median duration of response was 30 weeks and the median duration of survival was 52 weeks. There were no significant differences in treatment results between the consecutive groups of patients. The regimen was well tolerated for all doses of epirubicin. The main toxicities included alopecia (96%), nausea and vomiting (81%) and leukopenia (44%). Grade 4 haematological toxicity was observed in 3 patients (2.6%). No significant epirubicin dose-dependent side effects, except for mucositis were observed.
Collapse
Affiliation(s)
- J Jassem
- Radiotherapy Department, Medical Academy, Gdańsk, Poland
| | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Roszkowski K, Janic G, Jassem J, Karnicka-Młodkowska H, Szczepek B, Traczyk K, Zych J, Rowińska-Zakrzewska E. [Evaluation of the second line of treatment of patients with small cell carcinoma of the lung]. Pneumonol Pol 1989; 57:240-8. [PMID: 2560830] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Efficacy of second line therapy which included vepesid and adriamycin or vepesid, adriamycin and cis-platin, in small cell lung cancer was studied. Objective remission was seen in 35% of the once more treated patients. Analysis of survival time showed significant prolongation of it in cases treated once more in comparison with a group of patients with progression of the neoplastic process during primary therapy or patients not treated due to relapses of the process. The observed difference was bigger in patients that reacted with a remission to the second line therapy.
Collapse
|
9
|
Karnicka-Młodkowska H, Jassem J, Renkielska A. [Local toxicity of cytostatics]. Pol Tyg Lek 1988; 43:1066-8. [PMID: 3072541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
10
|
Jassem J, Karnicka-Młodkowska H, Mierzewski P, Decker E, Krawczyk K, Lisowska B, Malak K, Słupek A, Sokół A, Sosnowski K. [Comparison of 2 regimens of chemotherapy of small cell carcinoma of the lung: modified Hansen method and the ACOM method]. Pneumonol Pol 1988; 56:142-51. [PMID: 2842737] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
11
|
Karnicka-Młodkowska H, Jassem J, Dziewulska-Bokiniec A. [Cobalt radioisotope teletherapy of patients with metastases to the brain]. Neurol Neurochir Pol 1987; 21:193-6. [PMID: 3670524] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
The results are presented of palliative telecobaltotherapy in patients with metastases to the brain. The patients received a dose of 30 Gy in 10 fractions during 2 weeks. Clinical improvement was achieved in 28 out of 33 treated patients (85%). The survival time after the completion of radiotherapy was from 1 to 15 months, mean 5 months.
Collapse
|
12
|
Karnicka-Młodkowska H, Jassem J, Mierzewski P, Słupek A, Mierzwa W, Decker E, Prokop A, Krawczyk K, Kowal E, Firlik M. [Polychemotherapy using methotrexate, adriamycin, cyclophosphamide and CCNU (MACC) in patients with advanced adenocarcinoma and large cell carcinoma of the lung]. Pneumonol Pol 1986; 54:546-51. [PMID: 3035511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
13
|
Karnicka-Młodkowska H, Solska E, Jassem J, Kobierska A. [Telegammatherapy in patients with oral carcinoma]. Czas Stomatol 1984; 37:425-30. [PMID: 6598108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
14
|
Kobierska A, Karnicka-Młodkowska H, Solska E. [Radiotherapy of neoplasms of the central nervous system]. Neurol Neurochir Pol 1983; 17:85-90. [PMID: 6877504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
The authors present the results obtained by Co60 radiotherapy in 110 patients with the diagnosis of primary brain tumour, including 73 adults and 37 children aged up to 15 years. The follow-up time was from 2 to 8 years and it was survived by 40 patients (36.4%). Among 70 dying patients in 61 cases (87.1%) death occurred within two years after the treatment, which showed that therapeutic failures developed early in these cases. The 5-year survival rate was 24.4%. The best results were obtained in cases of astrocytoma, and the prognosis was better in children.
Collapse
|
15
|
Karnicka-Młodkowska H, Kobierska A. [Radiotherapy of central nervous system neoplasms. Indications for irradiation and technics]. Neurol Neurochir Pol 1982; 16:87-93. [PMID: 7133295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|
16
|
Karnicka-Młodkowska H, Stoba C, Cicholska A, Celińska W. [Laparotomy and splenectomy in children with Hodgkin's disease]. Pediatr Pol 1981; 56:1317-22. [PMID: 7339559] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
|
17
|
Karnicka-Młodkowska H, Zieliński T, Cicholska A, Kopacz A, Skokowski J, Stoba C. [Laparotomy with splenectomy in Hodgkin's disease]. Nowotwory 1979; 29:21-6. [PMID: 530853] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
18
|
Zieliński T, Krajewska B, Solska E, Karnicka-Młodkowska H. [MOPP chemotherapy of generalized Hodgkin's disease]. Nowotwory 1978; 28:453-9. [PMID: 733603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
19
|
Kobierska A, Krajewska B, Karnicka-Młodkowska H. [Case of ovarian cancer followed-up for a number of years]. Ginekol Pol 1978; 49:913-5. [PMID: 720908] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
|
20
|
Kobierska A, Karnicka-Młodkowska H, Solska E, Kruszewski T. [Moving strip technic in the irradiation of the abdominal cavity and the lungs]. Nowotwory 1978; 28:275-82. [PMID: 724532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
21
|
Karnicka-Młodkowska H, Kobierska A, Jedrzejewska E. [Late results of telecobaltotherapy in patients with inoperable lung cancer]. Pneumonol Pol 1978; 46:305-10. [PMID: 662750] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
22
|
Kobierska A, Karnicka-Młodkowska H, Zieliński T. [Telecobaltotherapy of bladder cancer]. Pol Przegl Chir 1976; 48:1281-7. [PMID: 981032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
23
|
Zieliński T, Kuśmierczuk M, Karnicka-Młodkowska H, Kobierska A, Kruszewski T. [Roentgenotherapy of laryngeal carcinoma]. Pol Przegl Radiol Med Nukl 1975; 39:381-6. [PMID: 1161560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|